Evidence map›Paper›PMID 38006571›Full record

ArticleAnnals of hematology2024

Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Hisashi Ishida, Yuki Arakawa, Daiichiro Hasegawa, Ikuya Usami, Yoshiko Hashii, Yasuyuki Arai, Satoshi Nishiwaki, Dai Keino, Keisuke Kato, Maho Sato and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 20 institutions in 1 country.

Hisashi IshidaDepartment of Pediatrics, Okayama University Hospital, Okayama, Japan.
Yuki ArakawaDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Daiichiro HasegawaDepartment of Hematology and Oncology, Center of Childhood Cancer, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
Ikuya UsamiDepartment of Pediatric Hematology and Oncology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.
Yoshiko HashiiDepartment of Pediatrics, Osaka International Cancer Institute, Osaka, Japan.
Yasuyuki AraiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Satoshi NishiwakiDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Dai KeinoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Keisuke KatoDivision of Pediatric Hematology and Oncology, Ibaraki Children's Hospital, Ibaraki, Japan.
Maho SatoDepartment of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, Japan.
Nao YoshidaDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
Keiko OkadaDepartment of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.
Moe HidakaDepartment of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
Yuki YuzaDepartment of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Kenichiro WatanabeDepartment of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
Junko TakitaDepartment of Pediatrics, Kyoto University Hospital, Kyoto, Japan.
Yoshiyuki KosakaDepartment of Hematology and Oncology, Center of Childhood Cancer, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
Naoto FujitaDepartment of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Junji TanakaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Atsushi SatoDepartment of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Toshihiko ImamuraDepartment of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465, Kajiichou, Hirokouji Kawaramachidori, Kamigyo-ku, Kyoto, 602-8566, Japan. imamura@koto.kpu-m.ac.jp.ORCID http://orcid.org/0000-0002-5727-4470
Kobe Children's Hospital · JPAichi Medical University · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHyogo Prefectural Amagasaki General Medical Center · JPIbaraki Children's Hospital · JPKanagawa Children's Medical Center · JPKanagawa Prefectural Hospital Organization · JPKyoto Prefectural University of Medicine · JPKyoto University · JPKyoto University Hospital · JPMiyagi Children's Hospital · JPNagoya University Hospital · JPOkayama University Hospital · JPOsaka City General Hospital · JPOsaka International Cancer Institute · JPOsaka Women's and Children's Hospital · JPSaitama Children's Medical Center · JPShizuoka Children's Hospital · JPTokyo Metropolitan Children's Medical Center · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival rates of patients with Philadelphia chromosome-positive ALL (Ph+ALL) have improved considerably with the introduction of tyrosine kinase inhibitors (TKI); however, hematopoietic stem cell transplantation (HSCT) continues to play an important role. Reduced-intensity conditioning (RIC) regimens have been widely applied particularly for older patients, but their validity for children and adolescents with Ph+ALL has not been investigated. In this study, data from patients receiving HSCT for de novo Ph+ALL in first or second remission at ages younger than 25 years and with a history of pre-HSCT TKI therapy were retrospectively collected through the nationwide registry in Japan. In 265 patients who received myeloablative conditioning (MAC) and 33 patients receiving RIC, 5-year leukemia-free survival (LFS) rates were 67.3% and 79.8%, respectively (p = 0.142). Multivariate analysis of LFS, focusing on patients with good performance status, identified RIC as a significant prognostic factor for LFS (hazard ratio 0.32, p = 0.032), as well as older age, higher leukocyte count at diagnosis, and disease with additional chromosomal abnormalities. These trends were similar when we focused on patients who received prophylactic post-HSCT TKI treatment, as 5-year LFS was 81.0% for MAC and 84.4% for RIC (p = 0.748). In summary, HSCT with RIC regimen showed at least comparable LFS to HSCT with MAC regimen, and RIC was an independent favorable prognostic factor on multivariate analysis adjusting potential prognostic factors. While patient numbers were limited, our data suggest that RIC may be safely applied in this group, particularly combined with prophylactic post-HSCT TKI maintenance therapy.

Indexed as

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseAdolescentChildHumansPhiladelphia ChromosomeRetrospective StudiesTransplantation ConditioningAdolescentChildLymphoid leukemiaPhiladelphia chromosomeStem cell transplantation

Identifiers

PMID38006571
OpenAlexW4389001291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.